- /
- Supported exchanges
- / US
- / FBLG.NASDAQ
FibroBiologics, Inc. Common Stock (FBLG NASDAQ) stock market data APIs
FibroBiologics, Inc. Common Stock Financial Data Overview
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with FibroBiologics, Inc. Common Stock (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get FibroBiologics, Inc. Common Stock data using free add-ons & libraries
Get FibroBiologics, Inc. Common Stock Fundamental Data
FibroBiologics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -16 405 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get FibroBiologics, Inc. Common Stock Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-03-31
- EPS/Forecast: -1.355
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
FibroBiologics, Inc. Common Stock News
New
FibroBiologics Reports Positive Preclinical Results For HDF Spheroids In Treating Burn Wounds
(RTTNews) - FibroBiologics Inc. (FBLG), a clinical-stage biotechnology company, on Monday announced positive preclinical results for the topical use of human dermal fibroblast spheroids in treating bu...
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026
FibroBiologics, Inc. HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pendin...
FibroBiologics Announces Pricing of $3 Million Public Offering
HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pendi...
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement
FibroBiologics, Inc. Reverse Split Expected to Take Effect March 30, 2026 HOUSTON, March 25, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage bio...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.